At a glance of commentaryScientific background on the subjectThe mechanisms of refractory seizures and the causes in children with febrile infection-related epilepsy syndrome (FIRES) remain unclear and immune dysfunction may play a role.What this study adds to the fieldFIRES children have impaired TLR 3, 4, 7/8 and 9 responses that may relate to weakened phagocytosis and decreased T regulatory cells. Such TLR impairments can persist for more than 12 months.

Febrile infection-related epilepsy syndrome (FIRES) is a catastrophic epileptic encephalopathy with known febrile infection preceding the onset of refractory status epilepticus, but without evidence of identified infectious encephalitis. It is frequently associated with high mortality and morbidity, especially in areas where enterovirus, herpes simplex virus and influenza infections are endemic \[[@bib1], [@bib2], [@bib3]\]. The pathogenic mechanisms of FIRES including infection- or inflammatory-mediated process, metabolic disorders, monogenic epilepsy genes, genetic predisposition, and autoimmunity have been proposed but the definite cause remains unknown. There are increasing evidences suggest that the mechanism is caused by autoimmunity due to autoantibodies production against the neuronal surface of N-methyl-[d]{.smallcaps}-aspartate receptors (NMDARs), glutamic acid decarboxylase (GAD), or intracellular molecules such as amphiphysin, CRMP5 (Anti-CV2), and ANNA-1 (Anti-Hu). Some cases with underlying malignancy present as paraneoplastic syndromes and induce autoantibodies production against neurons leading to refractory seizures \[[@bib4]\]. However, the mechanism of refractory seizures remains unclear in over half of all cases \[[@bib2],[@bib4]\].

Experimental mice lacking IFN cytokines of IFN-α, IFN-β, and IFN-λ are predisposed to several viral infections \[[@bib5]\]. In human and mice anti-viral defense systems \[[@bib6], [@bib7], [@bib8]\], Toll-like receptor (TLR)3, TLR7, TLR8, and TLR9 can induce IFN cytokine production via the TLR-IFN pathway to resist various viral infections \[[@bib9]\]. Within the human TLR-IFN downstream pathway, autosomal recessive UNC93B1 \[[@bib10]\] and autosomal dominant TLR3 deficiencies \[[@bib11]\] were firstly found to predispose healthy patients to herpes simplex encephalitis (HSE), suggesting a redundancy in immunity to most other viral infections \[[@bib11], [@bib12], [@bib13], [@bib14], [@bib15]\]. After that, defective downstream TLR3 signaling caused by TRIF, TRAF3 and TBK1 mutations was subsequently discovered \[[@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19]\].

The aim of this study was to determine whether children with FIRES have defective TLR pathways unable to eradicate infection-related triggering factors and inhibit epileptogenesis, therefore leads to refractory seizures. We investigated their TLR responses in primary peripheral blood mononuclear cells (PBMCs) and secondary monocyte-derived dendritic cells (MDDCs) \[[@bib20],[@bib21]\] to convince the consistent findings.

Methods {#sec1}
=======

Patients {#sec1.1}
--------

We enrolled FIRES patients included the criteria of (1) fever (≥38 °C) during the acute phase of illness, (2) symptoms of consciousness changes in the acute phase of illness, (3) acute onset of seizures at least 2 days after an antecedent febrile infection in previously healthy children, (4) seizures were so frequent and evolved into refractory status epilepticus without a latent period, (5) absence of pathogens identified in the CSF, and (6) prolonged duration of acute illness lasting more than two weeks. Magnetic resonance imaging (MRI) study were arranged to evaluate if there were abnormal signal changes. The presence of associated pathogens were investigated in the blood, cerebrospinal fluid (CSF), throat and anal swab cultures, paired serology and pathogenic PCR, including HSV, EBV, CMV, influenza, adenovirus, varicella, and mycoplasma pneumoniae. Anti-neural autoantibodies consisting of metabotropic glutamate receptor 5 (mGluR 5), dipeptidyl-peptidase-like protein-6 (DPPX), and γ-aminobutyric acid-A receptor (GABAAR). N-methyl-[d]{.smallcaps}-aspartate receptor (NMDAR), γ-aminobutyric acid-B receptor (GABABR), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), leucine-rich glioma inactivated protein 1 (LGI1), and contactin-associated protein-like 2 (CASPR2) were detected.

Those patients with febrile seizures, non-refractory epilepsy with and without underlying encephalitis/encephalopathy were enrolled as the controls. The Institutional Review Board (IRB) of Chang Gung Memorial Hospital approved this study, and all of the participants provided written informed consent.

Basic immunologic function {#sec1.2}
--------------------------

Peripheral blood samples (15 ml) from the enrolled patients and age-matched controls were drawn and analyzed within 24 h of the onset of refractory seizures and before the initiation of intravenous immunoglobulin (IVIG) and methylprednisolone pulse therapy. PBMCs were isolated by Ficoll-Hypaque (Pharmacia Biotech, Piscataway, NJ) centrifugation. RPMI 1640 supplemented with 10% fetal calf serum (FCS; Hyclone, UT), 2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin (complete medium) was used as complete culture media for further analysis.

To induce lymphocyte proliferation, PBMCs (10^5^/well) were incubated with the indicated concentrations of PHA, ConA, PWM or/and CD3CD28 for 3 days, or Candida antigen and BCG vaccine for 7 days. Lymphocyte subsets (all antibodies purchased from Pharmingen, San Jose, CA) were assessed by flow cytometry as previously described \[[@bib22], [@bib23], [@bib24]\], including CD3+, CD4+, CD8+, CD19+, CD45, CD45RO+, CD45RA+, CD27+, CD16 + CD56+ (natural killer cells) and T regulatory cells (Treg; CD4+FOXP3+).

To assess the effect of surface TLR responses on phagocytosis, pathogenic particles of BODIPY-labeled *Staphylococcus aureus* (through TLR2) or *Escherichia coli* (TLR4) (Molecular Probes, Eugene, OR) were incubated in a constant ratio of 10 to 1 polymorphonuclear cells (2 × 10^6^) for 2 h at room temperature in the presence of their own sera (for opsonization) as previously described \[[@bib25]\].

Expression of TLR1-9 on PBMCs {#sec1.3}
-----------------------------

Antibodies for human TLR and isotype controls were purchased from Imgenex Corp. (phycoerythrin-conjugated \[PE\]-conjugated TLR1-8) and eBioscience (PE-conjugated TLR9, San Diego, CA). TLR1, TLR2, TLR4, TLR5, and TLR6 were detected using surface staining, and TLR3, TLR7, TLR8 and TLR9 by intracellular staining. For intracellular staining, PBMCs were fixed in 4% formaldehyde for 15 min and permeabilized with 0.1% saponin for 30 min on ice. For both protocols, the cells were incubated with the corresponding TLR antibodies. A total of 10,000 viable lymphocytes were collected and analyzed by flow cytometry (FACSCalibur, BD Biosciences Corp., San Jose, CA).

TLR ligand stimulation {#sec1.4}
----------------------

To determine TLR responses, two stimulating dosages of TLR1-9 agonists or media only at a log range (except for TLR4 agonist) were chosen to test the dose-dependent effect on PBMCs (3 × 10^5^) in 100 μl complete media at 37 °C for 24 h: 1.0, 10 ug/ml Pam3CSK4 (TLR1/2 ligand, Invivogen, San Diego, CA); 1.0, 10 ug/ml poly (I:C) (TLR3 ligand, Sigma-Aldrich Co., St. Louis, MO); 1.0 ug/ml LPS (TLR4 ligand, Invitrogen, San Diego, CA); 0.1, 1.0 ug/ml flagellin (TLR5 ligand, Calbiochem Corp., San Diego, CA); 0.1, 1.0 ug/ml zymosan (TLR2/6 ligand, Invitrogen, San Diego, CA); 1.0, 10 ug/ml R848 (TLR7/8 ligand, Invitrogen, San Diego, CA); and 1.0, 10 ug/ml ODN 2216 (TLR9 ligand, Coley Pharmaceuticals Wellesley, MA). IL-6, IL-8, IL-10, IL-12, TNF-α., IFN-γ (R & D Systems, Minneapolis, MN), INF-α and INF-β (TFB, Fujirebio, Inc., Tokyo) production was assessed by ELISA as previously described \[[@bib26],[@bib27]\]. Every condition was performed in duplicate. P \< 0.05 was thought of significance by unpaired t tests (Graph Pad 4.0).

Development and stimulation of monocyte-derived dendritic cells {#sec1.5}
---------------------------------------------------------------

Compared to PBMCs, MDDCs have the potential to mount the TLR response \[[@bib28], [@bib29], [@bib30]\]. Thus, CD14+ monocytes were purified using a Monocyte Isolation Kit II (BD Biosciences Corp.), grown in GM-CSF (50 ng/ml) and IL-4 (25 ng/ml) in culture media (each 10^5^/ml) for 6 days and replaced every other day. CD14-FITC, HLA-DR-PE, CD11b-PE and CD80-PE (all punched from BD Biosciences Corp.) were utilized to evaluate the status of maturation in monocyte-derived dendritic cells (MDDCs) \[[@bib28],[@bib31]\] which resulted in increased expressions of HLA-DR, CD80, and CD11b but a decreased expression of CD14 \[[Fig. 1](#fig1){ref-type="fig"}\]. The expression of TLR and cytokine production from the MDDCs stimulated by TLR3, TLR4, TLR7/8, and TLR9 agonists were also evaluated to investigate whether these results paralleled with those in the PBMCs.Fig. 1Using monocyte (CD14) isolation, more homogenous monocytes (82.1%) were obtained from PBMCs (12.7%). **(A)** The percentage of CD14+ staining in isolated monocytes decreased in the monocyte-derived dendritic cells (MDCCs). **(B)** In contrast to CD14 expression, the expressions of CD11b, CD80 and HLA-DR (MHC class II) obviously increased in parallel with the maturation of MDDCs after co-culture with GM-CSF and IL-4 for 6 days. The results were similar in both patients and controls.Fig. 1

Results {#sec2}
=======

Patient characteristics {#sec2.1}
-----------------------

Five (one female) FIRES children were enrolled. All of them had episodes of status epilepticus, abnormal imaging results ([Fig. 2](#fig2){ref-type="fig"}), and/or epileptiform discharges in electroencephalography (EEG) ([Table 1](#tbl1){ref-type="table"}). None of the patients had neutropenia, lymphopenia, or hypogammaglobulinemia, however two had naïve CD4+ lymphopenia and four had lower Treg cells.Fig. 2Representative encephalitis/encephalopathy image in CT showed that (A) multiple asymmetrical areas (T2-hyperintensity and subtle T1-hypointensities) in the temporal and occipital cortical lobes in case 1; (B) Bilateral uncal and tonsillar herniations compressing the brain stem through foramen magnum in case 3; (C) Multiple asymmetrical areas in the bilateral caudate heads, lentiform nuclei, posterior thalamus and multiple cortical areas of bilateral frontal, parietal, occipital and subinsular regions in case 4; (D) Hyperintensities in the bilateral putamen, right hipppocampus, and bilateral anterior temporal cortex with interval atrophic change; Cavity change of the bil putaminal lesions in case 5.Fig. 2Table 1Clinical and significant laboratory features in FIRES patients with refractory seizures.Table 1GenderCase 1/MCase 2/FCase 3/MCase 4/MCase 5/MAge2Y11M2Y9M3Y3M13Y2M7Y1MFever+++++Status Epilepticus+++++CSF*WBC/RBC (5--10 high power view)*3/0**12**/17/0**23**/1**18**/3*Sugar*4251576348*Protein (8--*32 mg/ml*)*192925**4752***IgG index (* \< *.7)*0.370.420.390.410.37*Identified pathogens*NegativeNegativeNegativeNegativeNegativeImaging findings \[MRI\]Encephalitis[b](#tbl1fnb){ref-type="table-fn"}Non-significantEncephalitis[b](#tbl1fnb){ref-type="table-fn"}\
Uncal and tonsillar herniationEncephalitis[b](#tbl1fnb){ref-type="table-fn"}Post-encephalitis atrophyEEG*Cortical dysfunction*+++*Focal epileptiform*+++Hematology[d](#tbl1fnd){ref-type="table-fn"}*WBC (1000/ul)*1.5 (5.0--15.5)17.0 (5.0--15.5)1.27 (5.0--15.5)7.9 (4.5--13.5)11.7 (4.5--13.5)*S/L*43/2780/1073/2178/1673/22*Hb (g/dL)*10.9 (11.5--12.5)13.1 (11.5--12.5)14,4 (11.5--12.5)13.6 (13.0--14.5)15.5 (11.5--13.5)*PLT (1000/ul)*338 (150--350)242 (150--350)482 (150--350)146 (150--350)260 (150--350)Biochemistry*CRP*78.22.814.886.54.0*D-dimer (* \< 250 mg/ml*)***934741117232692047***GOT/GPT (60/40 U/L)*35/1937/1228/21**134/77163/125***BUN/Cr (mg/dL)*3.1/0.358.4/0.218.4/0.423.9/1.37.3/0.3*Ca/P/Mg (mg/dL)*9.1/4.7/1.69.7/3.2/1.79.5/3.8/1.98.2/4.0/1.69.3/3.8/1.8Immunologic data[c](#tbl1fnc){ref-type="table-fn"}*IgG*65092410909591042*IgG2*160253153259208*IgA*61.885.9147162114*IgM*12614115252.7102.3*IgE*1170UN89780.742.7*CD4CD4*5RA*% (* \> *.15%)*26.516.2**8.4[10.8]{.ul}**24.2*CD4CD45RO%*8.710.18.310.010.5*CD4FOXP3% (2--8%)***1.21.40.8[0.7]{.ul}**2.1*CD19CD27%*4.82.95.41.42.3*Memory T%*8.510.28.510.29.8*CD19%*32.137.262.739.818.2*Memory B%*4.93.05.91.52.4*NK%*3.72.81.84.05.1PhagocytosisE coli (87--99%)8462577971Staphy aureus (92--99%)7548436466Associated virus*Throat culture*AdenovirusEnterovirus*Serology IgM*MycoplasmaMycoplasma, HSVDetectable autoantibodies:*Anti-TPO*------+--*Anti-GAD*----------*Anti-neuro*[a](#tbl1fna){ref-type="table-fn"}----------Admission (days)*Intense care unit*1157532128*General unit*26249841IICP event----+++ (hemorrhage)TreatmentAnti-epileptic drugs (AEDs)Phenobarbital, phenytoin,\
levetiracetamPhenobarbital, phenytoin, levetiracetamPhenobarbital, phenytoin, valproatePhenobarbital, phenytoin,\
levetiracetamValproate, levetiracetam, topiramate, clonazepam, oxcarbazepine,SteroidspulsepulsepulsepulsepulseIVIG+++++Alternative**Hypothermia**Seizure frequency (per week)The first week**2124382129**The week of the last visit34523[^1][^2][^3][^4][^5]

All the patients had elevated D-dimers and liver enzymes due to hypoxia during the frequent seizure episodes. CSF cultures and PCR amplifications did not reveal any pathogens despite of mild CSF pleocytosis (WBC \>10/ml) was noted in three patients. However, adenovirus, enterovirus (in two throat cultures), mycoplasma pneumoniae, and HSV (in two serologic IgM elevations) were detected in three patients and sub-clinical infection was not excluded in the other two patients. Aside from AEDs, IVIG and methylprednisolone pulse therapy followed by prednisolone 0.5--2 mg/kg/day for 1--4 months decreased the frequency of seizures and interrupted the status epilepticus, especially in patient 3 who had uncal and tonsillar herniation.

TLR expressions and responses in PBMCs {#sec2.2}
--------------------------------------

The expressions of TLR 1--9 in the patients were similar to those of the controls, including those with febrile seizures with or without underlying encephalitis/encephalopathy (as a representative demonstration in [Supplemental Fig. 1](#appsec1){ref-type="sec"}). INF-β was not detectable in any patient. The TLRs responses generally trended to decrease and be significantly lower in TLR3 (in terms of IL-6, IL-8, INF-α, and INF-γ), TLR4 (INF-γ), TLR7/8 (INF-α, INF-γ and IL-12p40) and TLR9 (IL-6, INF-α, and INF-γ) pathways by their respective agonists while compared to those of the controls ([Fig. 3](#fig3){ref-type="fig"}, [Supplemental Table 1](#appsec1){ref-type="sec"}).Fig. 3Significantly lower (*p* \< 0.05; unpaired test) scatter diagrams of cytokine production (pg/ml) through TLR3, TLR4, TLR7/8, and TLR9 signaling in PBMCs from children with febrile infection-related syndrome.Fig. 3

Maturation of MDDCs and cytokine production {#sec2.3}
-------------------------------------------

Interestingly in blank medium, the production of IL-6 and IFN-γ was significantly lower and the others trended to be relatively low in the MDDCs, implying insufficient MDDC development. TLR3 (in term of IL-6, IL-8, INF-α, INF-γ and TNF-α), TLR4 (IL-12p40), TLR7/8 (INF-α and IL-12p40), and TLR9 (IL-6, IL-8, INF-α, and IL-12p40) responses also significantly decreased (in [Fig. 4](#fig4){ref-type="fig"} and [Supplemental Table 2](#appsec1){ref-type="sec"}). The intracellular TLR3, TLR7/8, and TLR9 expressions in the PBMCs and MDDCs were similar (71--99%) in the patients and controls (in [Fig. 5](#fig5){ref-type="fig"} and [Supplemental Fig. 1](#appsec1){ref-type="sec"}).Fig. 4Significantly lower (*p* \< 0.05; unpaired test) scatter diagrams of cytokine production (pg/ml) in blank and through TLR3, TLR4, TLR7/8, and TLR9 signaling in MDDCs from patients with febrile infection-related epilepsy syndrome (FIRES).Fig. 4Fig. 5The intracellular TLR3, TLR7, and TLR9 expressions in the MDDCs of patients with refractory epilepsy and in the controls (representative NC2 with encephalitis and non-refractory epilepsy) were similar.Fig. 5

The TLR expressions and functions of the PBMCs and MDDCs were evaluated again when the patients were in the seizure-free status after 12 months' treatment. Their expressions and cytokine profiles from the TLR responses in stable status were consistent with those in the refractory status (data not shown).

Discussion {#sec3}
==========

Children with FIRES showed impaired TLR3, TLR4, TLR7/8, and TLR9 responses. These observations in our patients inferred that anti-RNA viral cytokine profile of TLR responses to the associated pathogens of adenovirus, enterovirus, and herpes simplex behaving as TLR3, TLR7/8 and TLR9 agonists were down-regulated \[[@bib29], [@bib30], [@bib32], [@bib33]\]. Expectedly, decreased pro- and inflammatory cytokines of IL-6, IL-8, INF-α, and TNF-α through these impaired TLR3, TLR7/8, and TLR9 pathways could attenuate phagosome-associated responses \[[@bib34]\] reflecting on their diminished phagocytosis (i.e., TLR2 for *S. aureus* and TLR4 for *E. coli* in [Table 1](#tbl1){ref-type="table"}). As well as that lower number of naïve T cells increased susceptibility to viral infections, weakened phagocytosis was not able to effectively eradicate pathogens in time and therefore accumulate damaged debris, especially virus pathogens. By the mimicking mechanisms, prolonged exposure to such damaged debris behaving as epitopes cross-reactive to neural components could induce autoimmunity to central neurons. Furthermore, lower number of Treg cells in our patients lack sufficient suppression to counteract such unwanted autoimmune or/and inflammation responses \[[@bib35]\]. These findings could partially explain why adenovirus, enterovirus, herpes simplex virus, and mycoplasma pneumoniae were detectable in the throat and serology rather than in the CSF, and how these pathogen-debris mimicking epitopes attract autoantibodies into central neural system to attack central neurons, and subsequently orchestrate refractory seizures \[[@bib34], [@bib35], [@bib36]\].

In other words, permeability of the blood--brain barrier (BBB) can increase the sympathetic over-activity due to frequent seizures and make lymphocytes and/or some unrecognized anti-neural antibodies influx into the CSF to attack neurons and augment the vicious cycle in the periods of frequent seizure episodes or even status epilepticus \[[@bib37]\]. In such conditions, our patients have elevated protein, lymphocytic pleocytosis, or oligoclonal IgG bands in the CSF that are compatible with immune-mediated-like encephalitis. Except down-regulated cytokines of TLR response, our patients share mutual manifestations of febrile infection-related epilepsy syndrome (FIRES), characterized by pharmacoresistant seizures, neither detectable CSF pathogens nor antibodies \[[@bib38]\]. Suggested treatments to modulate immune dysregulation and neutralize harmful antibodies include steroids, IVIG, immuno-suppressants, plasmapheresis, and B cell deletion (anti-CD20) regimen \[[@bib39],[@bib40]\]. After IVIG and methylprednisolone pulse therapy followed by low-dose prednisolone and AEDs, the frequency of seizures was reduced to 2--5 episodes per week.

Notably, TLR4 signaling was grossly intact but significantly decreased IFN-γ and IL12-p40 production implying insufficient IFN-γ-IL12/23 circuits. Such subtle impairment of the IFN-γ-IL12/23 circuit seems not to reach the threshold to develop the phenotype of Mendelian susceptibility to mycobacterial infections (MSMD), presenting with recurrent intracellular salmonella, mycobacterial, varicella and/or opportunistic fungal infections \[[@bib41]\].

There are some limitations in this study. First, dissecting peripheral plasmacytoid and myeloid dendritic cells with relatively stronger TLR responses in the peripheral blood, would be more real and representative. However, such sub-populations are extremely few in younger children, and separating these dendritic cells from the peripheral blood to individually evaluate each TLR response would be technically difficult and more laborious. Instead, whole PBMCs were used and MDDCs were grown *in vitro* to ensure consistency. Tissue fibroblasts will be alternative ways to speculate these TLR responses. Second, the patients were prescribed with AEDs to treat seizures. Although the effects of the AEDs on TLR responses in the PBMCs could not completely be omitted, cytokine-grown MDDCs *in vitro* after 5-day-culture may have almost obviated these AEDs effects, if any. Third, in all of the enrolled patients, candidate genes responsible for the defective TLR3 signaling, including at least the coding regions of UNC93B1, TLR3, TRIF, TRAF3 and TBK1 genes \[[@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19]\] were wild in spite of similar phenotypes with TRAF3 mutations. Cognate common downstream signaling of TLR3, TLR7/8, TLR9 or/and TLR4, is a logical approach to search for novel and causal molecules by targeting exome sequencing. Lastly, due to the small case numbers enrolled in our study, large-scale studies are still warranted to validate our results.

In conclusion, children with febrile infection-related epilepsy syndrome (FIRES) in this study are found to have impaired TLR3, TLR4, TLR7/8, and TLR9 responses and thus relate to weakened phagocytosis and lower T regulatory cells. Patients with such TLR-related immune impairment may considerably benefit from treatment with immuno-modulators such as IVIG and steroid pulse therapy. Further investigations on the mechanisms of effective treatment will be merited.
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[^1]: The numbers underlined in bold italics indicate that they are higher than the normal range but below CD4CD45RA naïve cells.

[^2]: Anti-neural autoantibodies included metabotropic glutamate receptor 5 (mGluR 5), dipeptidyl-peptidase-like protein-6 (DPPX), and γ-aminobutyric acid-A receptor (GABAAR). N-methyl-[d]{.smallcaps}-aspartate receptor (NMDAR), γ-aminobutyric acid-B receptor (GABABR), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), leucine-rich glioma inactivated protein 1 (LGI1), and contactin-associated protein-like 2 (CASPR2).

[^3]: Cortical fluid-attenuated inversion recovery (FLAIR) or T2 multifocal lesions consist with encephalitis/encephalopathy.

[^4]: All patients had normal lymphocyte proliferation to mitogens (PHA, ConA, and PWM), antigens and CD3CD28).

[^5]: The standard range is based on Aquino J: The Harriet Lane Handbook, Philadelphia, Mosby, 2009.
